Transcatheter aortic valve implantation.

Authors

  • Thomas M Snow Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, UK
  • Neil Moat Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, UK
  • Sarah Barker Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, UK
  • Alison Duncan Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, UK
  • Carlo Di Mario Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, UK

Abstract

[first paragraph of article]

Aortic valve (AV) disease is a common condition with its prevalence, particularly aortic stenosis increasing exponentially with advancing age. A decade ago conventional aortic valve replacement (AVR) was the only treatment when medical management failed and symptoms developed. More than half of the patients potentially eligible for surgery have coexistent conditions making them unsuitable or very high-risk candidates. Balloon aortic valvuloplasty had too rapid a rate of restenosis to make it a viable long-term alternative. It was therefore occasionally used as a bridge or test to assess suitability for AVR in patients with severe but potentially reversible left ventricular (LV) dysfunction or comorbidities.

Downloads

Published

2017-01-02

Issue

Vol. 2012 No. 1 (2012)

Section

Review articles

License

This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.